Doctors are using molecular testing to personalize treatment decisions for patients with advanced prostate cancer [1].
This shift toward precision medicine allows clinicians to identify which patients will respond best to specific therapies, potentially reducing the use of ineffective treatments and improving survival rates [1, 2, 3].
Dr. Jacob Orme of the Mayo Clinic in Rochester, Minnesota, is utilizing these tools to determine if patients should receive specific interventions such as docetaxel or immunotherapy [1]. By analyzing the genetic makeup of the tumor, providers can move away from a one-size-fits-all approach to cancer care.
Liquid biopsies play a critical role in this process by allowing doctors to monitor tumor evolution over time [2, 3]. These non-invasive tests detect circulating tumor DNA in the blood, providing a real-time view of how the cancer is changing. This capability enables the medical team to adjust therapies as the disease evolves, rather than relying on static snapshots from a single tissue biopsy [2, 3].
Gene-expression signatures are also being applied to further refine these decisions [1, 3]. These signatures help identify the specific biological drivers of a patient's cancer, which informs the selection of targeted drugs. The goal is to match the right drug to the right patient at the right time [1].
Regulatory bodies have begun recognizing the impact of these technological advancements. On July 9, 2025, the U.S. FDA granted Artera breakthrough device designation for an AI-powered prostate cancer test [4]. This designation is intended to accelerate the development of tools that provide more significant advantages over existing alternatives.
As these molecular tools become more integrated into standard clinical practice, the focus remains on improving patient outcomes through a deeper understanding of the molecular landscape of the disease [1, 2].
“Molecular testing is being used to personalize and improve treatment decisions for advanced prostate cancer.”
The integration of serial liquid biopsies and AI-powered diagnostics marks a transition from reactive to proactive oncology. By treating prostate cancer as a dynamic, evolving target rather than a static condition, clinicians can pivot treatments in real-time, potentially extending the window of efficacy for chemotherapy and immunotherapies.
